NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides Presentation at Spartan Capital Investor Conference 2025
TL;DR
NanoViricides presents at Spartan Capital Investor Conference, offering investors early access to a company developing broad-spectrum antiviral drugs with significant market potential.
NanoViricides uses nanoviricide technology to create antiviral drugs that prevent viral escape, with lead candidate NV-387 advancing toward Phase II clinical trials for multiple respiratory viruses.
NanoViricides' broad-spectrum antiviral platform could revolutionize treatment for numerous viral diseases, potentially saving lives and reducing global healthcare burdens.
NanoViricides is developing nanoviricide drugs that work like guided missiles against viruses, targeting everything from COVID and flu to Ebola and rabies.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. (NYSE American: NNVC) will present at the Spartan Capital Investor Conference on November 3, 2025, at 9:45 a.m. ET in New York City.
NanoViricides is a clinical-stage company developing broad-spectrum antiviral drugs using special purpose nanomaterials called nanoviricides to prevent viral escape.
The lead candidate is NV-387 for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, plus MPOX/Smallpox, while NV-HHV-1 is being developed for shingles treatment.
The company's nanoviricide technology is based on intellectual property from TheraCour Pharma, creating special purpose nanomaterials for antiviral therapy that are designed to prevent viral escape.
The company is currently focused on advancing NV-387 into Phase II human clinical trials, but cannot project exact IND filing dates due to dependence on external collaborators and consultants.
The company is developing drugs against oral/genital Herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, Rabies, Dengue fever, Ebola, and holds exclusive licenses for multiple other viruses.
The company licenses technology from TheraCour Pharma for specific antiviral applications and has obtained broad, exclusive, sub-licensable field licenses for drugs developed in several licensed fields.
Drug development is extremely lengthy and requires substantial capital, with no assurance that candidates will show sufficient effectiveness and safety for human clinical development or that lab results will lead to successful products.
The full press release is available at https://ibn.fm/cnCIM, and more company information can be found at www.nanoviricides.com.
Curated from InvestorBrandNetwork (IBN)
